QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
QQQ   307.12 (-0.53%)
AAPL   157.65 (-0.40%)
MSFT   275.23 (-0.42%)
META   200.68 (-1.06%)
GOOGL   101.03 (-1.40%)
AMZN   97.24 (-0.82%)
TSLA   189.19 (-1.37%)
NVDA   264.10 (-0.46%)
NIO   9.20 (+3.02%)
BABA   98.40 (+14.26%)
AMD   94.56 (-2.12%)
T   18.72 (-0.79%)
F   11.60 (+0.69%)
MU   59.28 (-0.85%)
CGC   1.81 (-3.72%)
GE   93.14 (-0.18%)
DIS   94.82 (-0.84%)
AMC   5.15 (+13.19%)
PYPL   72.70 (-0.82%)
PFE   39.99 (-0.57%)
NFLX   323.52 (-1.26%)
NASDAQ:TROV

Cardiff Oncology - TROV Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.46
▼
$1.53
50-Day Range
$1.19
▼
$24.71
52-Week Range
$0.70
▼
$3.46
Volume
100,072 shs
Average Volume
648,892 shs
Market Capitalization
$16.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TROV stock logo

About Cardiff Oncology (NASDAQ:TROV) Stock

Cardiff Oncology, Inc. is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan in 1999 and is headquartered in San Diego, CA.

Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Stock News Headlines

January 13, 2023 | forbes.com
Cardiff Oncology
December 14, 2022 | seekingalpha.com
Cardiff Oncology: Staying The Course
March 28, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
October 16, 2022 | markets.businessinsider.com
Clear Channel Outdoor And 2 Other Penny Stocks Insiders Are Aggressively Buying
September 29, 2022 | finance.yahoo.com
Cardiff Oncology, Inc. (CRDF)
September 24, 2022 | seekingalpha.com
CRDF Cardiff Oncology, Inc.
August 25, 2022 | msn.com
Looking Into Cardiff Oncology's Return On Capital Employed
August 22, 2022 | seekingalpha.com
Cardiff Oncology: Down But Not Out
March 28, 2023 | Investor Place Media (Ad)
Biden To Unleash "Choke Point" Operation On America?
Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.
July 28, 2022 | finance.yahoo.com
Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
May 31, 2022 | stocknews.com
5 Oncology Stocks Wall Street Predicts Will Rally 135% or More
October 20, 2020 | finance.yahoo.com
Cardiff Oncology Presents Positive Efficacy and Biomarker Data from mCRPC Trial Demonstrating Ability of Onvansertib to Overcome Zytiga® Resistance
October 13, 2020 | seekingalpha.com
List Of Concerns About Cardiff Oncology's Plk1 Inhibitor - Seeking Alpha
October 9, 2020 | streetinsider.com
BioMedNewsBreaks – Cardiff Oncology Inc. (NASDAQ: CRDF) Announces Pricing of Underwritten Public Offering - StreetInsider.com
September 30, 2020 | marketwatch.com
Global Cell-Free DNA Testing Market Phenomenal Growth Prospects, Opportunities, SWOT Study and Volume| Agilent Technology, Allenex, Biocept
September 29, 2020 | marketwatch.com
Liquid Biopsy Market Size 2020 : Top Manufacturers, Industry Share, Regional Analysis, Types and Applications and Forecasts to 2025
September 29, 2020 | marketwatch.com
Europe Liquid Biopsy Market Size, Growth, Opportunity and Forecast to 2025
September 16, 2020 | streetinsider.com
Form 8-K Cardiff Oncology, Inc. For: Sep 15 - StreetInsider.com
September 15, 2020 | finance.yahoo.com
Cardiff Oncology to Host Key Opinion Leader Call Discussing KRAS-Mutated Colorectal Cancer and Highlighting Data from Onvansertib Phase 1b/2 Trial
September 14, 2020 | globenewswire.com
Liquid Biopsy Market Growth Rate of 23.80% by 2026 Global Industry Size, Share, Trends, COVID-19 Analysis and Technology Advancements by QIAGEN, MDxHealth, CareDx, Inc., Immucor, Inc., Menarini Silicon Biosystems, Guardant Health, Myriad Genetics - GlobeNewswire
September 14, 2020 | streetinsider.com
Form 8-K Cardiff Oncology, Inc. For: Sep 14 - StreetInsider.com
August 24, 2020 | finance.yahoo.com
Global Liquid Biopsy Executive And Consultant Guides 2020 - Yahoo Finance
August 20, 2020 | marketwatch.com
Industry Report: Liquid Biopsy market Size, Share and Growth to exceed US $3,051.1 Mn by 2025
August 18, 2020 | finance.yahoo.com
What Kind Of Shareholders Hold The Majority In Cardiff Oncology, Inc.'s (NASDAQ:CRDF) Shares?
August 4, 2020 | finance.yahoo.com
Cardiff Oncology to Participate in Fireside Chat at the Virtual BTIG Biotechnology Conference
July 30, 2020 | finance.yahoo.com
Cardiff Oncology to Participate in the William Blair Biotech Focus Conference - Yahoo Finance
June 15, 2020 | finance.yahoo.com
Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML
See More Headlines
Receive TROV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiff Oncology and its competitors with MarketBeat's FREE daily newsletter.

TROV Company Calendar

Last Earnings
2/27/2020
Today
3/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological Products, Except Diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TROV
CUSIP
N/A
CIK
1213037
Web
www.trovagene.com
Phone
(858) 952-7570
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($2.80)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-16,410,000.00
Net Margins
-3,688.31%
Pretax Margin
N/A
Return on Equity
-202.00%
Return on Assets
-122.92%

Debt

Debt-to-Equity Ratio
0.12
Current Ratio
2.37
Quick Ratio
2.37

Sales & Book Value

Annual Sales
$250,000.00
Price / Sales
64.30
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.94 per share
Price / Book
1.55

Miscellaneous

Outstanding Shares
11,011,000
Free Float
N/A
Market Cap
$16.08 million
Optionable
Optionable
Beta
1.04

Key Executives

  • Mark Erlander
    Chief Executive Officer & Director
  • Vicki Kelemen
    Chief Operating Officer & Executive Vice President
  • Brigitte Lindsay
    Secretary & Vice President-Finance

Key Competitors

View All Competitors













TROV Stock - Frequently Asked Questions

How were Cardiff Oncology's earnings last quarter?

Cardiff Oncology, Inc. (NASDAQ:TROV) posted its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. Cardiff Oncology had a negative net margin of 3,688.31% and a negative trailing twelve-month return on equity of 202.00%.

When did Cardiff Oncology's stock split?

Shares of Cardiff Oncology reverse split on the morning of Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Cardiff Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiff Oncology investors own include XOMA (XOMA), Inovio Pharmaceuticals (INO), Advanced Micro Devices (AMD), NVIDIA (NVDA), OPKO Health (OPK), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), Zynerba Pharmaceuticals (ZYNE), Amarin (AMRN) and Idera Pharmaceuticals (IDRA).

What is Cardiff Oncology's stock symbol?

Cardiff Oncology trades on the NASDAQ under the ticker symbol "TROV."

What is Cardiff Oncology's stock price today?

One share of TROV stock can currently be purchased for approximately $1.46.

How much money does Cardiff Oncology make?

Cardiff Oncology (NASDAQ:TROV) has a market capitalization of $16.08 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

How can I contact Cardiff Oncology?

Cardiff Oncology's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The official website for the company is www.trovagene.com. The medical research company can be reached via phone at (858) 952-7570 or via email at ir@trovagene.com.

This page (NASDAQ:TROV) was last updated on 3/28/2023 by MarketBeat.com Staff